In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).
Government policy is geared towards expanding the uptake of unbranded generics, which are likely to play a key role in the new universal health insurance scheme, which is due to be phased in from January 2014.
CONTENTS
4 EXECUTIVE SUMMARY
4 Key findings
5 MARKET SIZE
6 GENERICS DRIVERS AND RESISTORS
6 Drivers
6 Resistors
8 KEY GENERICS PLAYERS
9 BIOSIMILARS
10 BIBLIOGRAPHY